Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Lupin Completes Acquisition of VISUfarma

MUMBAI, India and LONDON and ROME and ZUG, Switzerland, April 2, 2026 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty...

2026-04-02 15:00 4780

Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association's 2026 Scientific Sessions

* Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association's 2026 Scientific Sessions. * The presentation will be delivered by W. Timothy Garvey, MD, a g...

2026-04-02 12:04 7419

Telix Appoints David Gill as Non-Executive Director

MELBOURNE, Australia and INDIANAPOLIS, April 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May...

2026-04-02 06:59 5621

Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint

SUZHOU, China, April 1, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceu...

2026-04-01 22:44 6233

Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

- Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic dermatitis (AD) and other type 2 inflammatory skin diseases - - BBT001 achieved rapid, deep, a...

2026-04-01 21:00 7485

Sino Biological ProPure™ Endotoxin-Free Proteins: The "Invisible Guardian" of Biopharmaceuticals

HOUSTON, April 1, 2026 /PRNewswire/ -- After months of meticulous work, your cells suddenly behave unpredictably, or your mouse models develop fever and systemic inflammation during critical studies. The hidden culprit may be endotoxin, the lipopolysaccharide (LPS) from gram-negative bacteria. Ev...

2026-04-01 18:30 4429

Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma

SHANGHAI, March 31, 2026 /PRNewswire/ -- 31 March 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, highly selective, oral small-molecule FGFR4 inhibitor irpagratinib (ABSK-011), has been granted Orphan Drug Desig...

2026-04-01 10:02 5738

NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development

PRINCETON, N.J. and TOKYO, April 1, 2026 /PRNewswire/ -- NJ Bio, Inc. ("NJ Bio"), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services ("Aji Bio‑Pharma"), a leading provider of biopharmaceutical manufacturing services and platform technologies...

2026-04-01 07:00 4817

NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development

Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland

* Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters * Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support * Plans further investments to add capabilities and strengthe...

2026-03-31 22:00 5791

Dalton Pharma Services Expands Aseptic Powder Fill-Finish Capacity with RoboFil™ system in Toronto

A fully automated aseptic fill-finish platform delivers greater speed, flexibility, and quality for the manufacturing of clinical supplies and commercial products. TORONTO, March 31, 2026 /PRNewswire/ -- Dalton Pharma Services today announced the successful installation of its RoboFil™ aseptic p...

2026-03-31 22:00 3574

Dalton Pharma Services Expands Aseptic Powder Fill-Finish Capacity with RoboFil™ system in Toronto

Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2

BEIJING and BRIDGEWATER, N.J., March 31, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating investigative once-weekly insulin GZR4 Injection, have successfully met their pre-specified primary endpo...

2026-03-31 21:50 5040

BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives

XI'AN, China, March 31, 2026 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading provider of bio-ingredient solutions in the natural, health, and personal care industries, announced today that on February 4, 2026 it entered into a Cooperation Framework Agree...

2026-03-31 21:00 4664

Inaugural Rabies in Asia Conference to Be Held in Kuching

KUCHING, Malaysia, March 31, 2026 /PRNewswire/ -- Place Borneo Sdn Bhd, in collaboration with the Department of Veterinary Services Sarawak (DVSS), will host the 1st Rabies in Asia (RIA) 2026 in conjunction with the 5th Rabies in Borneo (RIB) 2026, taking place 29 September to 1 October 2026 at t...

2026-03-31 20:31 3880

3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone

SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc. (01530.HK ) today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a high-quality performance with bot...

2026-03-31 20:13 7160

Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026

HONG KONG, March 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results of health-related quality of life (HRQoL) data (Poster: 107P) from the HARMONi-2 study at the 2026 European Lung Cancer Congress (ELCC). The study evaluated ivonescimab, the company's...

2026-03-31 17:40 4512

SirPAD: Primary Results confirm the safety and efficacy of Sirolimus Coated Balloon in PAD

TAMPA, Fla., March 31, 2026 /PRNewswire/ -- Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world's largest randomised controlled trial of a Sirolimus-coa...

2026-03-31 16:27 4044

Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

* OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab * New anatomic data demonstrates OLN324 achieves faster, greater, and more durable re...

2026-03-31 08:00 5147

Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today a...

2026-03-30 21:53 9947

Tigermed Announces 2025 Annual Results

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annua...

2026-03-30 20:56 6881

Qyuns Therapeutics-B (02509) 2025 Revenue Surges Over 4-Fold; Adjusted Profit Reaches Approximately RMB356 Million, Turning a Profit Year-on-Year

TAIZHOU, China, March 30, 2026 /PRNewswire/ -- Qyuns Therapeutics-B (02509) announced its 2025 annual results. Revenue amounted to approximately RMB807 million, representing a 4.08-fold year-on-year increase. Gross profit reached approximately RMB714 million, a 6.75-fold increase year-on-year. Pr...

2026-03-30 12:39 8291

1 ... 21 22 232425 26 27 ... 344